2014 Data Epilepsy Treatment 
Cannabis Law Report
JANUARY 16, 2022
Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. This means Malaysia currently has no registered marijuana-based treatment.
Canna Care Docs
DECEMBER 16, 2020
It would feel like an out-of-body experience, except for one fact: your body is constantly reminding you of those symptoms you’ve been suffering from all this time, putting treatment on the back burner while you deal with life as we know it. Research is ongoing, but the existing data and anecdotal reports show potential.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Chronicles
JANUARY 2, 2019
drug regulators approved the first marijuana-based pharmaceutical to treat kids with a form of epilepsy, and billions of investment dollars poured into cannabis companies. It’s a non-psychoactive compound found in marijuana and hemp plants and used for treatment of certain medical problems. It’s not just the U.S.
Sensi Seeds
DECEMBER 10, 2018
They evaluate data, which is now available thanks to the efforts of the cannabis policy reform movement, and try to provide answers, especially to those who need them most, namely, medical patients. Consequently, they sorted the publications into three main groups: psychiatry, cancer treatment, and neurology.
Cannabis Law Report
SEPTEMBER 24, 2019
T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.
Cannabis Law Report
JANUARY 10, 2022
This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. List To Data Sources. Opportunity Analysis (2014-2020-2028). Such instances are projected to fuel market growth over the forecast period.
WeedAdvisor
APRIL 1, 2019
As anecdotal evidence began piling up, some companies decided that CBD’s reported effects on epilepsy (which has been heavily proven), anxiety, insomnia, pain and inflammation – among others – could work on dogs, cats and other pets. A study published in 2014 found possible antidepressant and anti-anxiety effects in animal models.
Expert insights. Personalized for you.
98 
Let's personalize your content